Feb 13 2026 This Week in Cardiology
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 13 February 2026
⏱️ 30 minutes
🧾️ Download transcript
Summary
Ticagrelor vs prasugrel, a new LAAC device, pulsed field ablation AF results, lifestyle intervention in AF, the term "provider" vs "doctor," and coffee are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I TUXEDO-2 Trial
- TUXEDO-2 Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2844869
- ISAR-REACT 5 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973
II VERITAS Study of Dual-Seal LAAO
- VERITAS Study https://doi.org/10.1016/j.jacep.2026.01.021
III PFA vs RF over 4 years
- Advent-LTO study https://www.nature.com/articles/s41591-026-04246-4
- ADVENT Study https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
- SPHERE PER-AF Study https://www.nature.com/articles/s41591-024-03022-6
SINGLE SHOT CHAMPION Study https://www.nejm.org/doi/full/10.1056/NEJMoa2502280 - BEAT PAROX-AF Trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829
IV What's in a Name — Use of the Term "Provider"
- Physicians Are Not Providers: The Ethical Significance of Names https://www.acpjournals.org/doi/10.7326/ANNALS-25-03852
V Coffee and Dementia Risk
- Coffee/Tea Intake and Dementia Risk https://jamanetwork.com/journals/jama/fullarticle/2844764
- Mandrola Commentary: Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709
VI Lifestyle interventions Post AF ablation
- Improving Outcomes of AF by Lifestyle Interventions https://academic.oup.com/eurheartj/article/47/6/669/8243674
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
| 0:05.7 | This podcast is intended for health care professionals only. |
| 0:08.8 | Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape. |
| 0:14.6 | Hi, everyone. |
| 0:16.0 | This is John Mandrolo from the Heart.org Medscape Cardiology, and this is this week in cardiology for February 14th, 2026. |
| 0:26.0 | This week, Ticagular v. Prosagrel, a new left atrial appendage closure device, PFAAAF ablation results, |
| 0:34.7 | lifestyle intervention in AFIB, the term provider versus doctor, and coffee. |
| 0:41.9 | I'll start with the Tuxedo 2 trial. Jam of Cardiology is published Tuxedo 2, trial of Ticagular versus |
| 0:49.7 | prosagrel, as the second antiplatlet drug with aspirin after coronary stenting in patients who have |
| 0:57.2 | diabetes and multivessel disease. Now one twist on the RCT of 1,800 patients was that it was done in |
| 1:04.6 | India. Now, as a neutral Martian, I like to study question because I see much more ticagular |
| 1:10.6 | use than Prasagrel. |
| 1:13.1 | But the German government-funded Isar React 5 trial was highly significant, |
| 1:18.9 | 36% higher rate of death am I in stroke with Ticagulor versus Prasagrel. |
| 1:25.0 | That trial was published in 2019 now seven years ago. Of course, I get the fact that |
| 1:30.9 | it's more complex logistics to give with prosaigril, but gee whiz, as I have said many times, |
| 1:37.1 | it shocks me that ticagular use is so much greater than prosaigril. Now, but that's not the only knock |
| 1:43.5 | on ticagular, right? In Plato, |
| 1:45.6 | which was ticagular versus clopidigril, the top line was that ticagular reduced the primary |
| 1:51.4 | endpoint of CV-death MI and stroke by 16%. But the Plato trial has legendary criticisms and |
| 1:58.9 | weaknesses, right? In U.S. patients, there were more deaths than the Ticagular group compared to Clopidigril, |
| 2:05.4 | the opposite of what was seen globally. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.